Iterum Therapeutics plc - FORM S-1 - EX-23.1 - CONSENT OF KPMG - May 1, 2018

Attached files

file filename
EX-10.5 - FORMS OF 2015 IRISH STOCK OPTION AGR, GRANT NOTICE AND NOTICE OF EXERCISE - Iterum Therapeutics plcd522368dex105.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - Iterum Therapeutics plcd522368dex211.htm
EX-10.17 - EMPLOYMENT TERMS - JEFFREY SCHAFFNIT - Iterum Therapeutics plcd522368dex1017.htm
EX-10.15 - EMPLOYMENT TERMS - JUDITH M. MATTHEWS - Iterum Therapeutics plcd522368dex1015.htm
EX-10.14 - EMPLOYMENT TERMS - MICHAEL W. DUNNE - Iterum Therapeutics plcd522368dex1014.htm
EX-10.12 - EMPLOYMENT TERMS - COREY N. FISHMAN - Iterum Therapeutics plcd522368dex1012.htm
EX-10.11 - FORM OF INDEMNITY AGREEMENT (INTERUM THERAPEUTICS US LIMITED) - Iterum Therapeutics plcd522368dex1011.htm
EX-10.10 - FORM OF INDEMNITY AGREEMENT (REGISTRANT) - Iterum Therapeutics plcd522368dex1010.htm
EX-10.9 - FORM OF 2018 RESTRICTED SHARE UNIT AWARD AGREEMENT - Iterum Therapeutics plcd522368dex109.htm
EX-10.8 - FORMS OF 2018 INT'L STOCK OPTION TERMS AND CONDITIONS AND GRANT NOTICE - Iterum Therapeutics plcd522368dex108.htm
EX-10.7 - FORMS OF 2018 U.S. STOCK OPTION TERMS AND CONDITIONS AND GRANT NOTICE - Iterum Therapeutics plcd522368dex107.htm
EX-10.6 - 2018 EQUITY INCENTIVE PLAN - Iterum Therapeutics plcd522368dex106.htm
EX-10.4 - FORMS OF 2015 U.S. STOCK OPTION AGR, GRANT NOTICE AND NOTICE OF EXERCISE - Iterum Therapeutics plcd522368dex104.htm
EX-10.3 - 2015 EQUITY INCENTIVE PLAN - Iterum Therapeutics plcd522368dex103.htm
EX-10.2 - AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT - Iterum Therapeutics plcd522368dex102.htm
EX-10.1 - PFIZER LICENSE AGREEMENT - Iterum Therapeutics plcd522368dex101.htm
EX-5.1 - FORM OF OPINION OF A&L GOODBODY - Iterum Therapeutics plcd522368dex51.htm
EX-4.1 - FORM OF ORDINARY SHARE CERTIFICATE OF REGISTRANT - Iterum Therapeutics plcd522368dex41.htm
EX-3.2 - FORM OF CONSTITUTION, POST - IPO - Iterum Therapeutics plcd522368dex32.htm
EX-3.1 - CONSTITUTION, AS CURRENTLY IN EFFECT - Iterum Therapeutics plcd522368dex31.htm
EX-1.1 - FORM OF UNDERWRITING AGREEMENT - Iterum Therapeutics plcd522368dex11.htm
S-1 - S-1 - Iterum Therapeutics plcd522368ds1.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Iterum Therapeutics plc (formerly Iterum Therapeutics Limited):

We consent to the use of our report dated March 9, 2018, with respect to the consolidated balance sheets of Iterum Therapeutics plc (formerly Iterum Therapeutics Limited) as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, changes in convertible preferred shares and shareholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2017, and the related notes (collectively, the consolidated financial statements), included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG

Dublin, Ireland

May 1, 2018

Iterum Therapeutics plc Reports